News | October 30, 2023
Pfizer and BioNTech announce data for mRNA-based vaccine program for influenza and COVID-19
The companies plan to start a pivotal Phase 3 trial in the coming months
The companies plan to start a pivotal Phase 3 trial in the coming months
Approval based on DESTINY-Lung02 results where AstraZeneca and Daiichi Sankyo’s Enhertu demonstrated a confirmed objective response rate of 49% and median duration of response of 16.8 months in previously treated patients
In the Phase 3 LIBRETTO-431 study, Retevmo more than doubled progression-free survival (PFS) compared to chemotherapy plus pembrolizumab in patients with advanced or metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC)
The company expects that this development could improve the strength of its application to the FDA for new drug approval
CB03 is a candidate drug for the treatment of ALS and other central nerve system (CNS) diseases
New Molecular biology lab launched, AIIA increased its work scope in form of MoUs
Investment is additive to KKR’s existing health care growth strategy
The vaccine further advances Pfizer’s vaccine portfolio and builds on more than 20 years of expertise and knowledge in the prevention of meningococcal disease
Three-point improvement achieved in Sex Ratio at Birth from 904 in 2017-19 to 907 in 2018-20
hey were educated about the 7- step hand-washing technique trainings
Subscribe To Our Newsletter & Stay Updated
